Molecular Mechanisms,Diagnosis,and Rational Approaches to Management of and Therapy for Charcot-Marie-Tooth Disease and Related Peripheral Neuropathies
Restricted accessReview articleFirst published online September, 2003
Molecular Mechanisms,Diagnosis,and Rational Approaches to Management of and Therapy for Charcot-Marie-Tooth Disease and Related Peripheral Neuropathies
During the last decade, 18 genes and 11 additional loci harboring candidate genes have been associated with Charcot-Marie-Tooth disease (CMT) and related peripheral neuropathies. Ten of these 18 genes have been identified in the last 2 years. This phenomenal pace of CMT gene discovery has fomented an unprecedented explosion of information regarding peripheral nerve biology and its pathologic manifestations in CMT. This review integrates molecular genetics with the clinical phenotypes and provides a flowchart for molecular-based diagnostics. In addition, we discuss rational approaches to molecular therapeutics, including novel biologic molecules (eg, small interfering ribonucleic acid [siRNA], antisense RNA, and ribozymes) that potentially could be used as drugs in the future. These may be applicable in attempts to normalize gene expression in cases of CMT type 1A, wherein a 1.5 Mb genomic duplication causes an increase in gene dosage that is associated with the majority of CMT cases. Aggresome formation by the PMP22 gene product, the disease-associated gene in the duplication cases, could thus be avoided. We also discuss alternative therapeutics, in light of other neurodegenerative disorders, to disrupt such aggresomes. Finally, we review rational therapeutic approaches, including the use of antioxidants such as vitamin E, coenzyme Q10, or lipoic acid to relax potential oxidative stress in peripheral nerves, for CMT management.
EmeryA.E.Population frequencies of inherited neuromuscular diseases—a world survey.Neuromuscul Disord1991; 1: 19–29.
2.
LupskiJ.R., GarciaC.A.Charcot-Marie-Tooth peripheral neuropathies and related disorders. In: ScriverC.R., BeaudetA.L., SlyW.S. editors. The metabolic and molecular bases of inherited disorders.8th ed.New York: McGraw-Hill; 2001. p. 5759–88.
3.
BoerkoelC.F., LupskiJ.R.Hereditary motor and sensory neuropathies. In: RimoinD.L., ConnerJ.M., PyeritzR.E., KorfB.R. editors. Principles and practice of medical genetics.4th ed.London: Harcourt; 2002. p. 3303–20.
4.
MirskyR., JessenK.R.The neurobiology of Schwann cells.Brain Pathol1999; 9: 293–311.
5.
SchererS.S., SalzerJ.L.Axon-Schwann cell interactions in peripheral nerve regeneration. In: lessenK.R., RichardsonW.D. editors. Glial cell development.Oxford: Oxford University Press; 1996. p. 299–330.
6.
MartiniR.The effect of myelinating Schwann cells on axons.Muscle Nerve2001; 24: 456–66.
7.
SchererS.S., ArroyoE.J.Recent progress on the molecular organization of myelinated axons.J Peripher Nerv Syst2002; 7: 1–12.
8.
BoerkoelC.F., TakashimaH., LupskiJ.R.The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy.Curr Neurol Neurosci Rep2002; 2: 70–7.
9.
JordanovaA., De JongeP., BoerkoelC.F.Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease.Brain2003; 126: 590–7.
10.
BoerkoelC.F., TakashimaH., NakagawaM.CMT4A: identification of a Hispanic GDAP1 founder mutation.Ann Neurol2003; 53: 400–5.
11.
GemignaniF., MarbiniA., Di GiovanniG.Charcot-Marie-Tooth disease type 2 with restless legs syndrome.Neurology1999; 52: 1064–6.
12.
UnciniA., Di GuglielmoG., Di MuzioA.Differential electrophysiological features of neuropathies associated with 17pl 1.2 deletion and duplication.Muscle Nerve1995; 18: 628–35.
AllanW.Relation of hereditary pattern to clinical severity as illustrated by peroneal atrophy.Arch Intern Med1939; 63: 1123–31.
15.
LupskiJ.R., de Oca-LunaR.M., SlaugenhauptS.DNA duplication associated with Charcot-Marie-Tooth disease type 1A.Cell1991; 66: 219–32.
16.
RaeymaekersP., TimmermanV., NelisE. and the, H.M.S.N. Collaborative Research Group. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type la (CMT la). The HMSN Collaborative Research Group.Neuromuscul Disord1991; 1: 93–7.
17.
PatelP.I., RoaB.B., WelcherA.A.The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A.Nat Genet1992; 1: 159–65.
18.
WiseC.A., GarciaC.A., DavisS.N.Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication.Am J Hum Genet1993; 53: 853–63.
19.
NelisE., Van BroeckhovenC., De JongheP.Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative studyEur J Hum Genet1996; 4: 25–33.
20.
HoogendijkJ.E., HenselsG.W., Gabreels-FestenA.A.W.M.De-novo mutation in hereditary motor and sensory neuropathy type I.Lancet1992; 339: 1081–2.
21.
ChanceP.F., AldersonM.K., LeppigK.A.DNA deletion associated with hereditary neuropathy with liability to pressure palsies.Cell1993; 72: 143–51.
22.
TysonJ., MalcolmS., ThomasP.K., HardingA.E.Deletions of chromosome 17p11.2 in multifocal neuropathies.Ann Neurol1996; 39: 180–6.
23.
ValentijnL.J., BaasF., WoltermanR.A.Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A.Nat Genet1992; 2: 288–91.
24.
RoaB.B., GarciaC.A., PentaoL.Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A.Nat Genet1993; 5: 189–94.
25.
RoaB.B., DyckP.J., MarksH.G.Dejerine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene.Nat Genet1993; 5: 269–73.
26.
SimonatiA., FabriziG.M., PasquinelliA.Congenital hypomyelination neuropathy with Ser72Leu substitution in PMP22.Neuromuscul Disord1999; 9: 257–61.
27.
NicholsonG.A., ValentijnL.J., CherrysonA.K.A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies.Nat Genet1994; 6: 263–6.
28.
AdlkoferK., FreiR., NeubergD.H.-HHeterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy.J Neurosci1997; 17: 4662–71.
29.
MagyarJ.P., MartiniR., RuelickeT.Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage.J Neurosci1996; 16: 5351–60.
30.
SeredaM., GriffithsI., PühlhoferA.A transgenic rat model of Charcot-Marie-Tooth disease.Neuron1996; 16: 1049–60.
31.
SanchoS., MagyarJ.P., AguzziA., SuterU.Distal axonopathy in peripheral nerves of PMP22-mutant mice.Brain1999; 122: 1563–77.
32.
KrajewskiK.M., LewisR.A., FuerstD.R.Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A.Brain2000; 123: 1516–27.
33.
KillianJ.M., TiwariP.S., JacobsonS.Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathyMuscle Nerve1996; 19: 74–8.
34.
SuterU., SnipesG.J., Schoener-ScottR.Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters.J Biol Chem1994; 269: 25795–808.
35.
PareekS., NotterpekL., SnipesG.J.Neurons promote the translocation of peripheral myelin protein 22 into myelin.J Neurosci1997; 17: 7754–62.
36.
YoshikawaH., DyckP.J.Uncompacted inner myelin lamellae in inherited tendency to pressure palsy.J Neuropathol Exp Neurol1991; 50: 649–57.
37.
ZoidlG., D'UrsoD., Blass-KampmannS.Influence of elevated expression of rat wild-type PMP22 and its mutant PMP22Trembler on cell growth of NIH3T3 fibroblasts.Cell Tissue Res1997; 287: 459–70.
38.
D'UrsoD., SchmalenbachC., ZoidlG.Studies on the effects of altered PMP22 expression during myelination in vitro.J Neurosci Res1997; 48: 31–42.
39.
D'UrsoD., PriorR., Greiner-PetterR.Overloaded endoplasmic reticulum-Golgi compartments, a possible pathomechanism of peripheral neuropathies caused by mutations of the peripheral myelin protein PMP22.J Neurosci1998; 18: 731–40.
40.
ColbyJ., NicholsonR., DicksonK.M.PMP22 carrying the Trembler or Trembler-J mutation is intracellularly retained in myelinating Schwann cells.Neurobiol Dis2000; 7: 561–73.
41.
SandersC.R., Ismail-BeigiF., McEneryM.W.Mutations of peripheral myelin protein 22 result in defective trafficking through mechanisms which may be common to diseases involving tetraspan membrane proteins.Biochemistry2001; 40: 9453–9.
42.
DicksonK.M., BergeronJ.J.M., ShamesI.Association of calnexin with mutant peripheral myelin protein-22 ex vivo: a basis for “gain-of-function” ER diseases.Proc Natl Acad Sci U SA2002; 99: 9852–7.
43.
RyanM.C., ShooterE.M., NotterpekL.Aggresome formation in neuropathy models based on peripheral myelin protein 22 mutations.Neurobiol Dis2002; 10: 109–18.
44.
TaylorJ.P., HardyJ., FischbeckK.H.Toxic proteins in neurodegenerative disease.Science2002; 296: 1991–5.
45.
BucciantiniM., GiannoniE., ChitiF.Inherent toxicity of aggregates implies a common mechanism for protein mis-folding diseases.Nature2002; 416: 507–11.
46.
ToblerA.R., LiuN., MuellerL., ShooterE.M.Differential aggregation of the Trembler and Trembler J mutants of peripheral myelin protein 22.Proc Natl Acad Sci U S A2002; 99: 483–8.
47.
IsaacsA.M., JeansA., OliverP.L.Identification of a new Pmp22 mouse mutant and trafficking analysis of a Pmp22 allelic series suggesting that protein aggregates may be protective in Pmp22-associated peripheral neuropathy.Mol Cell Neurosci2002; 21: 114–25.
48.
PereaJ., RobertsonA., TolmachovaT.Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A.Hum Mol Genet2001; 10: 1007–18.
49.
LemkeG., AxelR.Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin.Cell1985; 40: 501–8.
50.
LemkeG.Unwrapping the genes of myelin.Neuron1988; 1: 535–43.
51.
WarnerL.E., HilzM.J., AppelS.H.Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination.Neuron1996; 17: 451–60.
52.
MandichP., MancardiG.L., VareseA.Congenital hypomyelination due to myelin protein zero Q215X mutation.Ann Neurol1999; 45: 676–8.
53.
SzigetiK., SaifiG.M., ArmstrongD.Disturbance of muscle fiber type differentiation in congenital hypomyelinating neuropathy caused by a novel myelin protein zero mutation.Ann Neurol. [In press]
54.
Planté-BordeneuveV., Guiochon-MantelA.The Roussy-Lévy family: from the original description to the gene.Ann Neurol1999; 46: 770–3.
55.
MartiniR., ZielasekJ., ToykaK.V.Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies.Nat Genet1995; 11: 281–6.
56.
GieseK.P., MartiniR., LemkeG.Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons.Cell1992; 71: 565–76.
57.
FreiR., MotzingS., KinkelinI.Loss of distal axons and sensory Merkel cells and features indicative of muscle denervation in hindlimbs of P0-deficient mice.J Neurosci1999; 19: 6058–67.
58.
FilbinM.T., WalshF.S., TrappB.D.Role of myelin P0 protein as a homophilic adhesion molecule.Nature1990; 344: 871–2.
59.
ShapiroL., DoyleJ.P., HensleyP.Crystal structure of the extracellular domain from P0, the major structural protein of peripheral nerve myelin.Neuron1996; 17: 435–49.
60.
XuW., ShyM., KamholzJ.Mutations in the cytoplasmic domain of P0 reveal a role for PKC-mediated phosphorylation in adhesion and myelination.J Cell Biol2001; 155: 439–45.
61.
EkiciA.B., FuchsC., NelisE.An adhesion test system based on Schneider cells to determine genotype-phenotype correlations for mutated P0 proteins.Genet Anal1998; 14: 117–9.
62.
BruzzoneR., RessotC.Connexins, gap junctions and cell-cell signaling in the nervous system.Eur J Neurosci1997; 9: 1–6.
63.
NeuhausI.M., BoneL., WangS.The human connexin32 gene is. transcribed from two tissue-specific promoters.Biosci Rep1996; 16: 239–48.
64.
BergoffenJ., SchererS.S., WangS.Connexin mutations in X-linked Charcot-Marie-Tooth disease.Science1993; 262: 2039–42.
65.
Balice-GordonR.J., BoneL.J., SchererS.S.Functional gap junctions in the Schwann cell myelin sheath.J Cell Biol1998; 142: 1095–104.
66.
DahlG., MillerT., PaulD.Expression of functional cell-cell channels from cloned rat liver gap junction complementary DNA.Science1987; 236: 1290–3.
67.
SwensonK.I., JordanJ.R., BeyerE.C., PaulD.L.Formation of gap junctions by expression of connexins in Xenopus oocyte pairs.Cell1989; 57: 145–55.
68.
BruzzoneR., WhiteT.W., SchererS.S.Null mutations of connexin32 in patients with X-linked Charcot-Marie-Tooth disease.Neuron1994; 13: 1253–60.
69.
OmoriY., MesnilM., YamasakiH.Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects.Mol Biol Cell1996; 7: 907–16.
70.
AbramsC.K., BennettM.V.L., VerselisV.K., BargielloT.A.Voltage opens unopposed gap junction hemichannels formed by a connexin 32 mutant associated with X-linked Charcot-Marie-Tooth disease.Proc Natl Acad Sci U S A2002; 99: 3980–4.
AnziniP., NeubergD.H.-H, SchachnerM.Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32.J Neurosci1997; 17: 4545–51.
73.
KobsarI., MaurerM., OttT., MartiniR.Macrophage-related demyelination in peripheral nerves of mice deficient in the gap junction protein connexin 32.Neurosci Lett2002; 320: 17–20.
74.
NicholsonS.M., GomesD., de NechaudB., BruzzoneR.Altered gene expression in Schwann cells of connexin32 knockout animals.J Neurosci Res2001; 66: 23–36.
75.
MersiyanovaI.V., PerepelovA.V., PolyakovA.V.A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.Am J Hum Genet2000; 67: 37–46.
76.
De JongheP., MersivanovaI., NelisE.Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E.Ann Neurol2001; 49: 245–9.
77.
YoshiharaT., YamamotoM., HattoriN.Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals.J Peripher Nerv Syst2002; 7: 221–4.
78.
ZhuQ., Couillard-DespresS., JulienJ-PDelayed maturation of regenerating myelinated axons in mice lacking neurofilaments.Exp Neurol1997; 148: 299–316.
79.
LeeM.K., MarszalekJ.R., ClevelandD.W.A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease.Neuron1994; 13: 975–88.
80.
JulienJ-P, MushynskiW.E.Neurofilaments in health and disease.Prog Nucleic Acid Res Mol Biol1998; 61: 1–23.
81.
GeislerN., WeberK.Self-assembly in vitro of the 68,000 molecular weight component of the mammalian neurofilament triplet proteins into intermediate-sized filaments.J Mol Biol1981; 151: 565–71.
82.
CarpenterD.A., IpW.Neurofilament triplet protein interactions: evidence for the preferred formation of NF-L-containing dimers and a putative function for the end domains.J Cell Sci1996; 109: 2493–8.
83.
Perez-OlleR., LeungC.L., LiemR.K.H.Effects of Charcot-Marie–Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation.J Cell Sci2002; 115: 4937–46.
84.
LupskiJ.R.Axonal Charcot-Marie-Tooth disease and the neurofilament gene (NF-L).Am J Hum Genet2000; 67: 8–10.
85.
de WaeghS.M., LeeV.M.-Y, BradyS.T.Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells.Cell1992; 68: 451–63.
86.
SahenkZ., ChenL., MendellJ.R.Effects of PMP22 duplication and deletions on the axonal cytoskeleton.Ann Neurol1999; 45: 16–24.
87.
YinX., CrawfordT.O., GriffinJ.W.Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons.J Neurosci1998; 18: 1953–62.
88.
ZhaoC., TakitaJ., TanakaY.Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bß.Cell2001; 105: 587–97.
89.
BomontP., CavalierL., BlondeauF.The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.Nat Genet2000; 26: 370–4.
90.
FlaniganK.M., CrawfordT.O., GriffinJ.W.Localization of the giant axonal neuropathy gene to chromosome 16q24.Ann Neurol1998; 43: 143–8.
91.
ZorickT.S., SyroidD.E., ArroyoE.The transcription factors SCIP and Krox-20 mark distinct stages and cell fates in Schwann cell differentiation.Mol Cell Neurosci1996; 8: 129–45.
92.
KioussiC., GrussP.Making of a Schwann.Trends Genet1996; 12: 84–6.
93.
SwiatekP.J., GridleyT.Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20.Genes Dev1993; 7: 2071–84.
94.
Schneider-MaunouryS., TopilkoP., SeitandouT.Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain.Cell1993; 75: 1199–214.
95.
TopilkoP., Schneider-MaunouryS., LeviG.Krox-20 controls myelination in the peripheral nervous system.Nature1994; 371: 796–9.
96.
WarnerL.E., Mancias R ButlerI.J.Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies.Nat Genet1998; 18: 382–4.
97.
BelloneE., Di MariaE., SorianiS.A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease.Hum Mutat1999; 14: 353–4.
98.
TimmermanV., De Jonghe R CeuterickC.Novel mis-sense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype.Neurology1999; 52: 1827–32.
99.
WarnerL.E., SvarenJ., MilbrandtJ., LupskiJ.R.Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies.Hum Mol Genet1999; 8: 1245–51.
100.
VenkenK., Di MariaE., BelloneE.Search for mutations in the EGR2 corepressor proteins, NAB1 and NAB2, in human peripheral neuropathies.Neurogenetics2002; 4: 37–41.
101.
InoueK., TanabeY., LupskiJ.R.Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation.Ann Neurol1999; 46: 313–8.
102.
PingaultV., BondurandN., KuhlbrodtK.SOX10 mutations in patients with Waardenburg-Hirschsprung disease.Nat Genet1998; 18: 171–3.
103.
InoueK., ShiloK., BoerkoelC.F.Congenital hypomyelinating neuropathy, central dysmyelination, and Waardenburg-Hirschsprung disease: phenotypes linked by SOX10 mutation.Ann Neurol2002; 52: 836–42.
104.
BondurandN., GirardM., PingaultV.Human connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10.Hum Mol Genet2001; 10: 2783–95.
105.
SlutskyS.G., KamarajuA.K., LevyA.Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype.J Biol Chem2003; 278: 8960–8.
106.
KuhlbrodtK., HerbarthB., SockE.Sox10, a novel transcriptional modulator in glial cells.J Neurosci1998; 18: 237–50.
GuilbotA., WilliamsA., RaviséN.A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease.Hum Mol Genet2001; 10: 415–21.
109.
TakashimaH., BoerkoelC.F., De JongheR.Periaxin mutations cause a broad spectrum of demyelinating neuropathies.Ann Neurol2002; 51: 709–15.
110.
DytrychL., ShermanD.L., GillespieC.S., BrophyP.J.Two PDZ domain proteins encoded by the murine periaxin gene are the result of alternative intron retention and are differentially targeted in Schwann cells.J Biol Chem1998; 273: 5794–800.
111.
ShermanD.L., BrophyP.J.A tripartite nuclear localization signal in the PDZ-domain protein L-periaxin.J Biol Chem2000; 275: 4537–40.
112.
GillespieC.S., ShermanD.L., BlairG.E., BrophyP.J.Periaxin, a novel protein of myelinating Schwann cells with a possible role in axonal ensheathment.Neuron1994; 12: 497–508.
113.
SchererS.S., XuY-T, BannermanP.G.C.Periaxin expression in myelinating Schwann cells: modulation by axon-glial interactions and polarized localization during development.Development1995; 121: 4265–73.
114.
GillespieC.S., ShermanD.L., Fleetwood-WalkerS.M.Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice.Neuron2000; 26: 523–31.
115.
BolinoA., MugliaM., ConfortiF.L.Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2.Nat Genet2000; 25: 17–9.
116.
BolinoA., LonieL.J., ZimmerM.Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy.Neurogenetics2001; 3: 107–9.
117.
KimS-A, TaylorG.S., TorgersenK.M., DixonJ.E.Myotubularin and MTMR2, phosphatidylinositol 3-phosphatases mutated in myotubular myopathy and type 4B Charcot-Marie-Tooth disease.J Biol Chem2002; 277: 4526–31.
118.
Berger R BonneickS., WilliS.Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1.Hum Mol Genet2002; 11: 1569–79.
119.
LaporteJ., BlondeauF., Buj-BelloA.Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human.Hum Mol Genet1998; 7: 1703–12.
120.
BolinoA., MarigoV., FerreraF.Molecular characterization and expression analysis of Mtmr2, mouse homologue of MTMR2, the myotubularin-related 2 gene, mutated in CMT4B.Gene2002; 283: 17–26.
121.
SenderekJ., BergmannC., WeberS.Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15.Hum Mol Genet2003; 12: 349–56.
122.
KalaydjievaL., GreshamD., GoodingR.N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lorn.Am J Hum Genet2000; 67: 47–58.
123.
KalaydjievaL., HallmayerJ., ChandlerD.Gene mapping in gypsies identifies a novel demyelinating neuropathy on chromosome 8q24.Nat Genet1996; 14: 214–7.
124.
ZhouD., SalnikowK., CostaM.Cap43, a novel gene specifically induced by Ni2+ compounds.Cancer Res1998; 58: 2182–9.
125.
LachatP., Shaw R GebhardS.Expression of NDRG1, a differentiation-related gene, in human tissues.Histochem Cell Biol2002; 118: 399–408.
126.
AgarwalaK.L., KokameK., KatoH., MiyataT.Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein.Biochem Biophys Res Commun2000; 272: 641–7.
127.
LiuH., NakagawaT., KanematsuT.Isolation of 10 differentially expressed cDNAs in differentiated Neuro2a cells induced through controlled expression of the GD3 synthase gene.J Neurochem1999; 72: 1781–90.
128.
CuestaA., PedrolaL., SevillaT.The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease.Nat Genet2002; 30: 22–5.
129.
BaxterR.V., Ben OthmaneK., RochelleJ.M.Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21.Nat Genet2002; 30: 21–2.
130.
VitelliR., ChiarielloM., LatteroD.Molecular cloning and expression analysis of the human Rab7 GTP-ase complementary deoxyribonucleic acid.Biochem Biophys Res Commun1996; 229: 887–90.
131.
VerhoevenK., De JongheR., CoenK.Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy.Am J Hum Genet2003; 72: 722–7.
132.
SharmaD.K., ChoudhuryA., SinghR.D.Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling.J Biol Chem2003; 278: 7564–72.
133.
MoriwakiY., BegumN.A., KobayashiM.Mycobacterium bovis bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein, SIMPLE, that bridges the missing link between lipopolysaccharide and p53-inducible gene, LITAF(PIG7), and estrogen-inducible gene, EET-1.J Biol Chem2001; 276: 23065–76.
134.
StreetV.A., GoldyI.D., GoldenA.S.Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies.Am I Hum Genet2002; 70: 244–50.
135.
StreetV.A., BennettC.L., GoldyI.D.Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C.Neurology2003; 60: 22–6.
136.
MyokaiF., TakashibaS., LeboR., AmarS.A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor a gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment.Proc Natl Acad Sci U S A1999; 96: 4518–23.
137.
De Sandre-GiovannoliA., ChaouchM., KozlovS.Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse.Am I Hum Genet2002; 70: 726–36.
138.
BonneG., Di BarlettaM.R., VarnousS.Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy.Nat Genet1999; 21: 285–8.
139.
MuchirA., BonneG., van der KooiA.J.Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B).Hum Mol Genet2000; 9: 1453–9.
140.
FatkinD., MacRaeC., SasakiT.Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.N Engl I Med1999; 341: 1715–24.
141.
CaoH., HegeleR.A.Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy.Hum Mol Genet2000; 9: 109–12.
142.
NovelliG., MuchirA., SangiuoloF.Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C.Am I Hum Genet2002; 71: 426–31.
143.
StuurmanN., HeinsS., AebiU.Nuclear lamins: their structure, assembly, and interactions.J Struct Biol1998; 122: 42–66.
144.
RoberR-A, WeberK., OsbornM.Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study.Development1989; 105: 365–78.
145.
BroersJ.L.V., MachielsB.M., KuijpersH.J.H.A- and B-type lamins are differentially expressed in normal human tissues.Histochem Cell Biol1997; 107: 505–17.
146.
CoatesP.J., HobbsR.C., CrockerJ.Identification of the antigen recognized by the monoclonal antibody BU31 as lamins A and C.J Pathol1996; 178: 21–9.
147.
SullivanT., Escalante-AlcaldeD., BhattH.Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy.I Cell Biol1999; 147: 913–20.
148.
PouliotI.J., YaoK.C., RobertsonC.A., NashH.A.Yeast gene for a Tyr-DNA phosphodiesterase that repairs to poisomerase I complexes.Science1999; 286: 552–5.
149.
InamdarK.V., PouliotI.J., ZhouT.Conversion of phosphoglycolate to phosphate termini on 3’ overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1.J Biol Chem2002; 277: 27162–8.
150.
InterthalH., PouliotI.I., ChampouxJ.J.The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily.Proc Natl Acad Sci U S A2001; 98: 12009–14.
151.
TakashimaH., BoerkoelC.F., JohnJ.Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy.Nat Genet2002; 32: 267–72.
152.
CaldecottK.W.DNA single strand break repair and spinocerebellar ataxia.Cell2003; 112: 7–10.
153.
VanceI.R., WilsonT.E.Yeast Tdp1 and Radl-Rad10 function as redundant pathways for repairing Top1 replicative damage.Proc Natl Acad Sci U S A2002; 99: 13669–74.
154.
LiuC., PouliotI.I., NashH.A.Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1.Proc Natl Acad Sci U S A2002; 99: 14970–5.
155.
HutchinsonF.Chemical changes induced in DNA by ionizing radiation.Prog Nucleic Acid Res Mol Biol1985; 32: 115–54.
156.
HowardH.C., MountD.B., RochefortD.The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum.Nat Genet2002; 32: 384–92.
157.
PearsonM.M., LuI., MountD.B., DelpireE.Localization of the K+-Cl- cotransporter, KCC3, in the central and peripheral nervous systems: expression in the choroid plexus, large neurons and white matter tracts.Neuroscience2001; 103: 481–91.
SorkinA., Von ZastrowM.Signal transduction and endocytosis: close encounters of many kinds.Nat Rev Mol Cell Biol2002; 3: 600–14.
162.
BoerkoelC.F., TakashimaH., GarciaC.A.Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation.Ann Neurol2002; 51: 190–201.
163.
GarciaC.A.Familial neuropathies. In: JohnsonR.T., GriffinsJ.W. editors. Current therapy in neurologic disease.5th ed.St. Louis: Mosby-Year Book; 1997. p. 386–8.
164.
LindemanE., SpaansF., ReulenJ.Progressive resistance training in neuromuscular patients. Effects on force and surface EMG.J Electromyogr Kinesiol1999; 9: 379–84.
165.
NjegovanM.E., LeonardE.I., JosephF.B.Rehabilitation medicine approach to Charcot-Marie-Tooth disease.Clin Podiatr Med Surg1997; 14: 99–116.
166.
SiegelI.M.Management of kineceptive loss in CMT with an elastic ankle support.Muscle Nerve1994; 17: 827.
167.
OatisC.A., SundbergD., OliverC., YerkesP.Conservative management in patients with Charcot-Marie-Tooth disorders. In: ParryG.J. editor. Charcot-Marie-Tooth disorders.Upland (PA): Charcot-Marie-Tooth Association; 1995. p. 103–16.
168.
MannD.C., HsuJ.D.Triple arthrodesis in the treatment of fixed cavovarus deformity in adolescent patients with Charcot-Marie-Tooth disease.Foot Ankle1992; 13: 1–6.
169.
WoodV.E., HueneD., NguyenJ.Treatment of the upper limb in Charcot-Marie-Tooth disease.J Hand Surg [Br]1995; 20: 511–8.
170.
BirchJ.G.Orthopedic management of neuromuscular disorders in children.Semin Pediatr Neurol1998; 5: 78–91.
171.
GuytonG.P., MannR.A.The pathogenesis and surgical management of foot deformity in Charcot-Marie-Tooth disease.Foot Ankle Clin2000; 5: 317–26.
172.
BackonjaM-MUse of anticonvulsants for treatment of neuropathic pain.Neurology2002; 59: S14–7.
173.
MellegersM.A., FurlanA.D., MailisA.Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.Clin J Pain2001; 17: 284–95.
174.
MattiaC., PaolettiF., ColuzziF., BoanelliA.New antidepressants in the treatment of neuropathic pain. A review.Minerva Anestesiol2002; 68: 105–14.
175.
AttalN.Chronic neuropathic pain: mechanisms and treatment.Clin J Pain2000; 16: S118–30.
176.
KollerW.C., HristovaA., BrinM.Pharmacologic treatment of essential tremor.Neurology2000; 54: S30–8.
177.
NakamuraY., ShimizuH., NishijimaC.Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity.Neurosci Lett2001; 304: 5–8.
178.
GrafW.D., ChanceP.F., LenschM.W.Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.Cancer1996; 77: 1356–62.
179.
NaumannR., MohmJ., ReunerU.Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.Br J Haematol2001; 115: 323–5.
180.
FireA., XuS., MontgomeryM.K.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature1998; 391: 806–11.
181.
OpalinskaJ.B., GewirtzA.M.Nucleic-acid therapeutics: basic principles and recent applications.Nat Rev Drug Discov2002; 1: 503–14.
182.
HeasmanJ.Morpholino oligos: making sense of antisense?Dev Biol2002; 243: 209–14.
183.
DesarnaudF., Do ThiA.N., BrownA.M.Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells.J Neurochem1998; 71: 1765–8.
SchenkD., BarbourR., DunnW.Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse.Nature1999; 400: 173–7.
186.
PepysM.B., HerbertJ., HutchinsonW.L.Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.Nature2002; 417: 254–9.
187.
RonD.Translational control in the endoplasmic reticulum stress response.J Clin Invest2002; 110: 1383–8.
188.
KaufmanR.J.Orchestrating the unfolded protein response in health and disease.J Clin Invest2002; 110: 1389–98.
189.
MaurerM., KobsarI., BerghoffM.Role of immune cells in animal models for inherited neuropathies: facts and visions.J Anat2002; 200: 405–14.
190.
JudeE.B., SelbyP.L., BurgessJ.Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.Diabetologia2001; 44: 2032–7.
191.
FolkersK., SimonsenR.Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies.Biochim Biophys Acta1995; 1271: 281–6.
192.
LissettC.A., ToogoodA.A., DidiM., ShaletS.M.Growth hormone replacement in an adult with mild growth hormone deficiency and hereditary motor and sensory neuropathy: growth hormone restores independent mobility.Horm Res1998; 50: 232–6.
193.
SanchoS., YoungP., SuterU.Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A.Brain2001; 124: 2177–87.
194.
TewsD.S., GoebelH.H., MeinckH.M.DNA-fragmentation and apoptosis-related proteins of muscle cells in motor neuron disorders.Acta Neurol Scand1997; 96: 380–6.
195.
TewsD.S., GoebelH.H.Apoptosis-related proteins in skeletal muscle fibers of spinal muscular atrophy.J Neuropathol Exp Neurol1997; 56: 150–6.
196.
TewsD.S.Apoptosis and muscle fibre loss in neuromuscular disorders.Neuromuscul Disord2002; 12: 613–22.
197.
WilliamsL.L., O'DoughertyM.M., WrightF.S.Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease.Neurology1986; 36: 1200–5.
198.
ReljanovicM., ReichelG., RettK.Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.Free Radic Res1999; 31: 171–9.
199.
HaslbeckK.M., SchleicherE.D., FriessU.NE-Carboxymethyllysine in diabetic and non-diabetic polyneuropathies.Acta Neuropathol2002; 104: 45–52.
200.
AntonellisA., EllsworthR.E., SambuughinN.Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V.Am J Hum Genet2003; 72: 1293–9.
201.
PulsI., JonnakutyC., LaMonteB.H.Mutant dynactin in motor neuron disease.Nat Genet2003; 33: 455–6.
202.
YoungP., GroteK., KuhlenbaumerG.Mutation analysis in Chariot-Marie-Tooth disease type 1: point mutations in the MPZ gene and the GJB1 gene cause comparable phenotypic heterogeneity.J Neurol2001; 248: 410–5.
203.
ChaouchM., AllalY., De Sandre-GiovannoliA.The phenotypic manifestations of autosomal recessive axonal Charcot-Marie-Tooth due to a mutation in Lamin A/C gene.Neuromuscul Disord2003; 13: 60–7.
204.
Auer-GrumbachM., WagnerK., Strasser-FuchsS.Clinical predominance of proximal upper limb weakness in CMT1A syndrome.Muscle Nerve2000; 23: 1243–9.
205.
PanasM., KalfakisN., KaradimasC., VassilopoulosD.Episodes of generalized weakness in two sibs with the C164T mutation of the connexin 32 gene.Neurology2001; 57: 1906–8.
206.
LaguenyA., LatourP., VitalA.Mild recurrent neuropathy in CMT1B with a novel nonsense mutation in the extracellular domain of the MPZ gene.J Neurol Neurosurg Psychiatry2001; 70: 232–5.
207.
MoutonP., TardieuS., GouiderR.Spectrum of clinical and electrophysiologic features in HNPP patients with the 17pll.2 deletion.Neurology1999; 52: 1440–6.
208.
PareysonD., TaroniF., BottiS.Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation.Neurology2000; 54: 1696–8.
209.
StojkovicT., LatourP., VandenbergheA.Sensorineural deafness in X-linked Charcot-Marie-Tooth disease with connexin 32 mutation (R142Q).Neurology1999; 52: 1010–4.
210.
ChaponF., LatourP., DiraisonP.Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene.J Neurol Neurosurg Psychiatry1999; 66: 779–82.
211.
KovachM.J., CampbellK.C.M., HermanK.Anticipation in a unique family with Charcot-Marie-Tooth syndrome and deafness: delineation of the clinical features and review of the literature.Am J Med Genet2002; 108: 295–303.
212.
KovachM.J., LinJ-P, BoyadjievS.A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness.Am J Hum Genet1999; 64: 1580–93.
213.
IonasescuW., SearbyC., GreenbergS.A.Dejerine-Sottas disease with sensorineural hearing loss, nystagmus, and peripheral facial nerve weakness: de novo dominant point mutation of the PMP22 gene.J Med Genet1996; 33: 1048–9.
214.
PingaultV., Guiochon-MantelA., BondurandN.Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: a developmental “neural crest syndrome” related to a SOX10 mutation.Ann Neurol2000; 48: 671–6.
215.
MisuK., YoshiharaT., ShikamaY.An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val).J Neurol Neurosurg Psychiatry2000; 69: 806–11.
216.
BoerkoelC.F., TakashimaH., BacinoC.A.EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy.Neurogenetics2001; 3: 153–7.
217.
HouldenH., KingR.H.M., WoodN.W.Mutations in the 5’ region of the myotubularin-related protein 2 (MTMR2) gene in autosomal recessive hereditary neuropathy with focally folded myelin.Brain2001; 124: 907–15.
218.
YenerG.G., Guiochon-MantelA., ObuzF.Phe 84 deletion of the PMP22 gene associated with hereditary motor and sensory neuropathy HMSN III with multiple cranial neuropathy: clinical, neurophysiological and magnetic resonance imaging findings.J Neurol2001; 248: 193–6.
